Skip to main content
M1 Kliniken AG logo

M1 Kliniken AG — Investor Relations & Filings

Ticker · M12 ISIN · DE000A0STSQ8 LEI · 529900W697S31A26WT02 F Human health and social work activities
Open in API
Filings indexed 165 across all filing types
Latest filing 2026-05-26 Share Issue/Capital Cha…
Country DE Germany
Listing F M12

About M1 Kliniken AG

https://www.m1-kliniken.de/en/index.html

M1 Kliniken AG is a provider of health services in the beauty sector, specializing in aesthetic medicine and plastic surgery. The company operates a chain of specialized medical centers offering a range of treatments, including non-surgical procedures like wrinkle and lip treatments, as well as surgical interventions such as breast corrections. The core of its business model is to provide affordable access to aesthetic treatments while maintaining high quality standards. In addition to its clinical services, the company also offers a portfolio of beauty products.

Recent filings

Filing Released Lang Actions
M1 Kliniken AG: Capital reduction through cancellation of treasury shares successfully completed
Share Issue/Capital Change Classification · 89% confidence The document is a corporate news announcement detailing a capital structure change: the cancellation of treasury shares and reduction of share capital. This fits the definition of “Share Issue/Capital Change” (SHA), which covers announcements regarding capital changes (including reductions, share issues, stock splits, etc.).
2026-05-26 English
M1 Kliniken AG publishes annual report for 2025: strong growth in EBIT (+29%) and earnings per share (+40%)
Report Publication Announcement Classification · 85% confidence The document is a corporate news release stating that M1 Kliniken AG has published its annual report for the 2025 financial year and provides only summary key figures (no full financial statements or detailed disclosures). It is an announcement of report publication rather than the report itself. Therefore, it falls under Report Publication Announcement (RPA).
2026-05-20 English
M1 Kliniken AG: Supervisory Board adopts annual financial statements 2025. Dividend proposal of EUR 1.20 per share
Notice of Dividend Amount Classification · 80% confidence The document is an ad-hoc inside-information announcement under MAR announcing that the Supervisory Board has adopted the 2025 financial statements and resolved to propose a dividend of EUR 1.20 per share to the Annual General Meeting. It is not the full annual report (10-K) nor a simple publication notice (RPA), and there is no vote result or management change. The core content is the dividend amount proposal. Therefore, it fits the “Notice of Dividend Amount” category.
2026-05-12 English
M1 Kliniken AG publishes preliminary figures for the 2025 financial year: strong growth in EBIT (+29%) and earnings per share (+40%)
Earnings Release Classification · 90% confidence The document is a corporate news release providing preliminary IFRS consolidated figures for the full 2025 financial year, highlighting key metrics (revenue, EBITDA, EBIT, EPS) and outlook, but does not constitute the full annual report itself. This matches the definition of an Earnings Release (ER) as an initial announcement of periodical financial results (key highlights only). FY 2025
2026-04-22 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Annual Report Classification · 100% confidence The document is a comprehensive annual report for M1 Kliniken AG for the fiscal year 2024. It includes the 'Bericht des Aufsichtsrates' (Supervisory Board Report), the 'Konzernlagebericht' (Group Management Report), and detailed sections on business segments, economic conditions, and financial performance. It is clearly the full annual report rather than an announcement or a summary, as it contains substantive financial and operational analysis. FY 2024
2026-02-05 German
M1 Kliniken AG: Completion of the Sale of 100% Subsidiary HAEMATO Pharm GmbH to PHOENIX group
M&A Activity Classification · 95% confidence The document is a corporate news announcement regarding the completion of a divestiture (the sale of a subsidiary, HAEMATO Pharm GmbH). This falls under M&A activity as it describes a completed transaction involving the disposal of a business unit. While it is a corporate news release, the specific content relates to a merger/acquisition/disposal event, making 'TAR' the most accurate classification.
2026-02-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.